Synthesis and properties of N-nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine ester as a prodrug of 5-fluorouracil for rectal administration
- PMID: 17182232
- DOI: 10.1016/j.ejpb.2006.11.002
Synthesis and properties of N-nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine ester as a prodrug of 5-fluorouracil for rectal administration
Abstract
N-Nicotinoyl-2-(5-fluorouracil-1-yl)-D,L-glycine (NFG) methyl-(NFGM), ethyl-(NFGE) and isopropyl esters (NFGIp) were synthesized and their potential as a prodrug of 5-fluorouracil (5-FU) for rectal administration was investigated. Chemical conversion proceeded either by elimination of (5-FU) or by hydrolysis of ester group. 5-FU was released from NFGIp, NFGE and NFGM 90.5%, 71.3% and 48.5% of the dose, respectively, in 80% human plasma and 79.8%, 56.3% and 31.6%, respectively, in pH 7.4 buffer solution after 48 h of incubation at 37 degrees C. Release of 5-FU occurred mainly from NFG esters but very slightly from NFG, which suggested that release of 5-FU was greatly dependent on the stability of the ester group against hydrolysis. Solubility (M) in pH 7.4 buffer solution was 0.13, 0.09 and 0.04 and apparent partition coefficient in 1-octanol/pH 7.4 buffer solution was 0.76, 1.61 and 4.2, respectively, for NFGM, NFGE and NFGIp, which were in the ranges suitable for rectal absorption. Plasma concentration (microg/mL) of NFGM, NFGE and NFGIp at 50 min after rectal administration to rats was 1.9, 4.6 and 6.7, respectively, and that for 5-FU was below the limit of detection. Their potential as prodrugs of 5-FU for rectal administration is suggested.
Similar articles
-
Synthesis and evaluation of N-acyl-2-(5-fluorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fluorouracil.J Pharm Sci. 2001 Nov;90(11):1787-94. doi: 10.1002/jps.1128. J Pharm Sci. 2001. PMID: 11745736
-
Synthesis and in vitro evaluation of N-nicotinoylglycyl-2-(5-fluorouracil-1-yl)-D,L-glycine as a colon-specific prodrug of 5-fluorouracil.J Drug Target. 2007 Apr;15(3):199-205. doi: 10.1080/10611860701197508. J Drug Target. 2007. PMID: 17454357
-
Preparation and evaluation of N(3)-O-toluyl-fluorouracil-loaded liposomes.Int J Pharm. 2008 Apr 2;353(1-2):243-50. doi: 10.1016/j.ijpharm.2007.11.017. Epub 2007 Nov 17. Int J Pharm. 2008. PMID: 18155370
-
The prodrugs of 5-fluorouracil.Curr Med Chem Anticancer Agents. 2002 Mar;2(2):267-310. doi: 10.2174/1568011023354146. Curr Med Chem Anticancer Agents. 2002. PMID: 12678747 Review.
-
5-Fluorouracil derivatives: a patent review.Expert Opin Ther Pat. 2012 Feb;22(2):107-23. doi: 10.1517/13543776.2012.661413. Epub 2012 Feb 14. Expert Opin Ther Pat. 2012. PMID: 22329541 Review.
Cited by
-
Optimization of 5-flurouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer.Int J Med Sci. 2010 Nov 22;7(6):398-408. doi: 10.7150/ijms.7.398. Int J Med Sci. 2010. PMID: 21103076 Free PMC article.
-
Physicochemical investigation of a novel curcumin diethyl γ-aminobutyrate, a carbamate ester prodrug of curcumin with enhanced anti-neuroinflammatory activity.PLoS One. 2022 Mar 18;17(3):e0265689. doi: 10.1371/journal.pone.0265689. eCollection 2022. PLoS One. 2022. PMID: 35303012 Free PMC article.
-
Design of oligothiophene-based tetrazoles for laser-triggered photoclick chemistry in living cells.Chem Commun (Camb). 2013 Nov 4;49(85):9920-2. doi: 10.1039/c3cc45752d. Chem Commun (Camb). 2013. PMID: 24036983 Free PMC article.
-
Synthesis and antitumor activity of amino acid ester derivatives containing 5-fluorouracil.Molecules. 2009 Aug 25;14(9):3142-52. doi: 10.3390/molecules14093142. Molecules. 2009. PMID: 19783913 Free PMC article.
-
An in vitro release study of 5-fluoro-uracil (5-FU) from swellable poly-(2-hydroxyethyl methacrylate) (PHEMA) nanoparticles.J Mater Sci Mater Med. 2009 May;20(5):1103-14. doi: 10.1007/s10856-008-3677-x. Epub 2009 Jan 10. J Mater Sci Mater Med. 2009. PMID: 19132508
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources